STAT3 and cancer: We demonstrate that TCN treatment inhibits the phosphorylation of STAT3 by directly binding to its SH2 domain, resulting in inhibition of dimerization, nuclear translocation, and transcriptional activity of STAT3, thereby inhibiting multiple cancer-related features in colorectal cancer development in vitro.